Acute Leukemia Clinical Trial
— PACE-ALOfficial title:
Patient Activation Through Counseling and Exercise - Acute Leukemia - Pilot Trial
The purpose of this pilot study is to test an exercise-based multidimensional intervention for patients with acute leukaemia undergoing consolidation chemotherapy in the context of outpatient management. Further, to test for safety, feasibility and preliminary effect on physical and functional capacity, and health related quality of life.
Status | Completed |
Enrollment | 20 |
Est. completion date | February 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients that are able to speak Danish > 18 years and newly diagnosed with acute leukæmia (MDS, AML, CMML, APL or ALL) - Normal EKG, blood pressure and pulse - Signed informed written consent Exclusion Criteria: - Medical reason that contraindicates physical activity - Patients diagnosed with a symptomatic cardiac disease within the last three months. - Documented bone metastasis - Dementia, psychotic - Cannot write or read Danish - Patients unable to carry out baseline tests |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Denmark | Copenhagen University Hospital | Copenhagen | |
Denmark | Herlev Hospital | Herlev |
Lead Sponsor | Collaborator |
---|---|
Universitetshospitalernes Center for Sygepleje | Lundbeck Foundation, Novo Nordisk A/S |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility - adherence rates | Percentage of intervention participation | Adherence to the intervention components from baseline to 6 weeks | Yes |
Secondary | Adverse events | Number and type of adverse events | baseline to 6 weeks | Yes |
Secondary | 6MWD | Change in distance in meter | Change from baseline in 6MWD at 6 weeks | Yes |
Secondary | Attrition | Number of patients that withdrew from the project | Withdrawal from the project from baseline to 6 weeks | Yes |
Secondary | Timed chair stand | Change in the number of repetitions | Change from baseline in timed chair stand at 6 weeks | Yes |
Secondary | Timed bicep curl | Change in number of repetitions | Change from baseline in timed bicep curl at 6 weeks | Yes |
Secondary | FACT-Anemia | Change in scores for quality of life/function | Change from baseline in FACT-An at 6 weeks | No |
Secondary | HADS | Change in scores for emotional wellbeing | Change from baseline in HADS at 6 weeks | No |
Secondary | SF36 | Change in scores for general health | Change from baseline in SF36 at 6 weeks | No |
Secondary | MDSAI | Change in scores for symptom burden | Change from baseline over time (1,2,3,4,5,6 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05088356 -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Active, not recruiting |
NCT01956630 -
Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Enrolling by invitation |
NCT01728402 -
Pathogenesis of Hematologic Malignancies
|
||
Active, not recruiting |
NCT03595800 -
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
|
Phase 3 | |
Completed |
NCT02440178 -
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia
|
Phase 2 | |
Recruiting |
NCT05071482 -
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
|
Phase 4 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Completed |
NCT03042676 -
Electronic Database for the Follow up of the ATG_FamilyStudy
|
||
Completed |
NCT04597086 -
Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients
|
N/A | |
Terminated |
NCT03588936 -
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
|
Phase 1 | |
Recruiting |
NCT05521204 -
Olverembatinib for FGFR1-rearranged Neoplasms
|
Phase 2 | |
Not yet recruiting |
NCT04084327 -
Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
|
||
Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 | |
Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|